Keywords: Sanofi-Aventis, Chattem, M&A, OTCs, Allegra, eplivanserin, idrabiotaparinux, Research, Insomnia, Atrial fibrillation

Sanofi-Aventis to buy consumer health firm Chattem for $1.9 billion, aiming for bigger role in OTC

Article | 22 December 2009

Print This

In a move that will take it up to fifth place in global consumer health care – and confirming its aims ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in